XBI:NYE-SPDR® S&P Biotech ETF (USD)

ETF | Health |

Last Closing

USD 82.56

Change

+0.08 (+0.10)%

Market Cap

N/A

Volume

8.00M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-06-05 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-0.18 (-0.14%)

USD 33.98B
FHLC Fidelity® MSCI Health Care In..

-0.05 (-0.08%)

USD 2.37B
FXH First Trust Health Care AlphaD..

-0.08 (-0.08%)

USD 0.90B
XHE SPDR® S&P Health Care Equipme..

+0.43 (+0.53%)

USD 0.17B
IDNA iShares Genomics Immunology an..

-0.11 (-0.53%)

USD 0.10B
XHS SPDR® S&P Health Care Service..

-0.06 (-0.06%)

USD 0.09B
SBIO ALPS Medical Breakthroughs ETF

+0.09 (+0.29%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.12 (-0.44%)

USD 0.04B
BBP Virtus LifeSci Biotech Product..

+0.20 (+0.34%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.18 (+0.91%)

USD 0.01B

ETFs Containing XBI

MATH Metalpha Technology Holdi.. 0.00 % 1.35 %

-0.11 (0%)

USD 0.11B
INAV 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -8.33% 10% F 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.33% 10% F 20% F
Trailing 12 Months  
Capital Gain -11.05% 14% F 20% F
Dividend Return 0.14% 19% F 2% F
Total Return -10.91% 14% F 18% F
Trailing 5 Years  
Capital Gain -19.77% 19% F 21% F
Dividend Return 0.46% 26% F 1% F
Total Return -19.32% 19% F 13% F
Average Annual (5 Year Horizon)  
Capital Gain -7.90% 14% F 10% F
Dividend Return -7.84% 14% F 7% C-
Total Return 0.06% 21% F 3% F
Risk Return Profile  
Volatility (Standard Deviation) 23.91% 19% F 39% F
Risk Adjusted Return -32.79% 14% F 9% A-
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.